Home

Curis, Inc. (CRIS)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Curis, Inc. (CRIS)

Go deeper and ask any question about CRIS

Company Performance

Current Price

as of Sep 13, 2024

$5.46

P/E Ratio

N/A

Market Cap

$32.65M

Description

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Metrics

Overview

  • HQLexington, MA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerCRIS
  • Price$5.46+9.42%

Trading Information

  • Market Cap$32.65M
  • Float99.82%
  • Average Daily Volume (1m)79,207
  • Average Daily Volume (3m)45,142
  • EPS-$8.24

Company

  • Revenue$10.16M
  • Rev Growth (1yr)15.89%
  • Net Income-$11.80M
  • Gross Margin97.09%
  • EBITDA Margin-489.00%
  • EBITDA-$12.45M
  • EV$53.70M
  • EV/Revenue5.29
  • P/EN/A
  • P/S3.13
Documents